NicOx SA Announces Results Of A Phase 2 Trial For NCX 4016 In PAOD

NicOx S.A. (Eurolist: NICOX) today announced that a phase 2 trial for NCX 4016 in Peripheral Arterial Obstructive Disease (PAOD) has not met its primary endpoint in terms of demonstrating a statistically significant advantage over placebo. The primary endpoint of the trial was the change in absolute treadmill walking distance after six months of treatment, versus placebo, compared to baseline. A statistically significant advantage was seen for NCX 4016 in a pre-defined sub-group of patients with type 2 diabetes. Full analysis of the data is ongoing, including an examination of pre-defined secondary end-points and safety and tolerability. NCX 4016 is a novel, proprietary, nitric oxide-donating derivative of acetylsalicylic acid, which NicOx is developing in a range of cardiovascular and related disorders.